Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series
Abstract
Cytomegalovirus (CMV) infection remains a common complication after kidney transplantation, particularly among high‐risk donor‐seropositive/recipient‐seronegative (D+/R−) recipients. Valganciclovir is the standard first‐line therapy; however, its use may be limited by hematological toxicity or impaired graft function. Maribavir is a recently approved antiviral agent with a distinct mechanism of action.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.